Developing targeted pharmacotherapies to personalize cancer care has become the mantra in oncology, and now a team of scientists from The Netherlands, Belgium, Germany, and Canada has taken the first step toward targeting radiotherapy dosages to individual patients by assessing the genetic characteristics of individuals with hypersensitivity to radiation therapy.
Sorafenib (Nexavar) significantly improved progression-free survival in patients with breast cancer, according to the results of the SOLTI-0701 study presented at the ECCO 15 – ESMO 34 Joint Congress by José Baselga, MD, ESMO president and a member of the ECCO executive committee, and head of oncology, Vall d’Hebron University Hospital, Barcelona, Spain.
In a poster presented at the ECCO 15 – ESMO 34 Joint Congress, KM Mallath and colleagues from the Department of Digestive Diseases and Clinical Nutrition, Tata Memorial Centre, Mumbai, India, noted that cancer pain is an important independent risk factor for poor performance status in newly diagnosed patients and significantly associated with malnutrition.
A meta-analysis of four phase II and III trials confirmed the benefit found for cetuximab added to platinum-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer (NSCLC). The findings were reported at the ECCO 15 - ESMO 34 Joint Congress by Jean-Louis Pujol, MD, of Montpellier Academic Hospital, Montpellier, France.
Although an FDA Reproductive Health Drugs Advisory Committee recommended in August against approving Amgen’s denosumab (Prolia) as a treatment to reduce bone complications in patients with advanced breast cancer, updated data presented today at ECCO/ESMO might elicit a different opinion from an ODAC panel, if convened.
Jetske Ruiterkamp, surgical resident, Jeroen Bosch Hospital, of The Netherlands and colleagues presented findings from a retrospective study that compared the rate of 5-year overall survival and reduction in the risk of death in women with stage IV breast cancer who underwent resection of their tumor compared with those who did not.
In men deemed at high risk for developing prostate cancer, the dual 5α-reductase inhibitor dutasteride reduced the risk of biopsy-detectable prostate cancer across multiple subgroups by 16% to 32%, according to a subgroup analysis of the REDUCE trial (Reduction by DUtasteride of prostate Cancer Events) presented at the ECCO 15 - ESMO 34 Joint Congress.
In a Scientific Symposium at ECCO/ESMO, researchers from the Netherlands Cancer Institute, Department of Molecular Carcinogenesis; Academic Medical Center, Department of Pathology; and MD Anderson Cancer Center, Department of Systems Biology, discussed the PI3K pathway as a factor in poor response or resistance to HER2-inhibitors such as trastuzumab (Herceptin).
Gefitinib, an oral tyrosine kinase inhibitor (TKI), is highly effective in patients with non-small-cell lung cancer (NSCLC) who harbor mutations of the EGFR gene (mEGFR), as demonstrated by a pooled analysis of four phase III studies and a separate phase III study presented at the ECCO 15 – ESMO 34 Joint Congress.